OpGen is an early commercial stage company using molecular testing and bioinformatics to assist healthcare providers to combat multi-drug resistant bacterial infections. The company’s products and services are designed to enable the rapid identification of hospital patients who are colonized or infected with life-threatening, multi-drug resistant organisms, or MDROs. OpGen’s lead product is the Acuitas™ MDRO Gene Test. Products in development include the Acuitas Lighthouse™ bioinformatics platform and the Acuitas Resistome test. In addition, the company has more than 10 years of experience mapping microbial, plant and human genomes.